Chinese(GB)     
Contact CFDA
   
HOME ABOUT CFDA WHAT'S NEW LAWS & REGULATIONS REGULATORY GUIDE DATA SEARCH SITE MAP
  Search      
Home >> What's New  
What's New
SFDA issues Guiding Opinions on Enhancing the Construction of Adverse Drug Reaction Monitoring System
2011-11-24
To implement the relevant requirements of the reform of the medical and health care system, further improve the adverse drug reaction reporting and monitoring system, improve the capability of monitoring, evaluation and safety alert, and ensure drug safety for the public, the State Food and Drug Administration (SFDA) recently issued the Guiding Opinions on Enhancing the Construction of Adverse Drug Reaction Monitoring System in accordance with the Provisions for Adverse Drug Reaction Reporting and Monitoring. The Guiding Opinions defines the guidelines, basic principles, general objectives, responsibilities, construction requirements, key emphasis and guarantee measures for enhancing the construction of adverse drug reaction monitoring system.
HOME | ABOUT CFDA | WHAT'S NEW | LAWS AND REGULATIONS | REGULATORY GUIDE | DATA SEARCH
| SITE MAP |
© CFDA
Constructed and Maintained by the Information Center of CFDA